Clarification of the Diagnosis using the Holter ECG Monitoring in a Doctor’s Practice
Keywords:
Coronary artery disease, Atypical manifestations, Arrhythmias, Holter ECG monitoringAbstract
Coronary artery disease (CAD) is one of the most common cardiovascular diseases, is associated with high mortality in the population, and often presents atypically. At the same time, CAD often leads to arrhythmias, the timely diagnosis of which is necessary to adjust treatment and to prevent life-threatening arrhythmias. Holter electrocardiogram (ECG) monitoring should be considered as one of the main and optimal methods aimed at detecting hidden changes in the heart muscle. We present two clinical cases that demonstrate the importance of Holter ECG monitoring in this patient category.
References
1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham study. Am Heart J. 1983;106:389-96.
2. Ghuran AV, Camm AJ. Ischaemic heart disease presenting as arrhythmias. Br Med Bull. 2001;59:193-210.
3. Shi H, Xia Y, Cheng Y, Liang P, Cheng M, et al. Global burden of ischaemic heart disease from 2022 to 2050: projections of incidence, prevalence, deaths, and disability-adjusted life years. Eur Heart J Qual Care Clin Outcomes. 2025;11:355-66.
4. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45:3314.
5. Arthur J. Moss, Shlomo Stern. Noninvasive electrocardiology: clinical aspects of holter monitoring. W.B. Saunders, MichiganUniversity. 1998.
6. Forslund L, Hjemdahl P, Held C, Björkander I, Eriksson SV, Rehnqvist N. Ischaemia during exercise and ambulatory monitoring in patients with stable angina pectoris and healthy controls. Gender differences and relationships to catecholamines. Eur Heart J. 1998;19:578-87.
7. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415-537.
8. Bocchino PP, Angelini F, Toso E. Atrial fibrillation and coronary artery disease: a review on the optimal use of oral anticoagulants. Rev Cardiovasc Med. 2021;22:635-48.
9. Potpara TS, Mujovic N, Proietti M, Dagres N, Hindricks G, et al. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, REDUAL PCI, and AUGUSTUS trials. Europace. 2020;22:33-46.
10. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381:1103-13.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
